Wells Fargo analyst Mohit Bansal lowered the firm’s price target on Merck (MRK) to $110 from $125 and keeps an Equal Weight rating on the shares. Merck’s Gardasil expectation reset is a step in right direction, but new investment would still need a narrative shift and Winrevair may not be enough to drive that, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck price target lowered to $120 from $140 at BofA
- MRK Earnings: Merck Stock Drops Despite Q3 Beat
- Merck Reports Steady Q3 2024 Growth Amid Challenges
- Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz
- Morning Movers: Roblox surges and Estee Lauder sinks following earnings